Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy
Journal of the American Heart Association · 2024
DOI: 10.1161/jaha.124.034518 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Naoto Kuyama und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan. Hauptthemen laut MEDLINE: Biomarkers, Natriuretic Peptide, Brain, Amyloid Neuropathies, Familial, Benzoxazoles. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background Although tafamidis treatment improves prognosis in patients with wild‐type transthyretin amyloid cardiomyopathy, an optimal surrogate marker monitoring its therapeutic effect remains unclear. This study investigated the association between changes in cardiac biomarkers, high‐sensitivity cardiac troponin T (hs‐cTnT) and B‐type natriuretic peptide (BNP) during the first year after tafamidis treatment and clinical outcomes. Methods and Results In 101 patients with wild‐type transthyretin amyloid cardiomyopathy receiving tafamidis at our institution, change in cardiac biomarkers from baseline to 1 year after tafamidis administration and its association with composite outcomes (composite of all‐cause death and hospitalization attributable to heart failure) was assessed. During the follow‐up period (median, 17 months), 16 (16%) patients experienced composite outcomes. The hs‐cTnT level significantly decreased at 1 year after tafamidis treatment, unlike the BNP level. The frequencies of increased hs‐cTnT and BNP levels were significantly higher in those with composite outcomes than in those without (44% versus 15%; P =0.01). Kaplan‐Meier survival analysis showed that patients in whom both hs‐cTnT and BNP levels increased at 1 year after tafamidis had a higher probability of composite outcomes compared with those with decreased hs‐cTnT and BNP levels (log‐rank P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan.
- Department of Medical Information Science, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan.
- Department of Diagnostic Radiology, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan.
- Department of Neurology, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan.
- Faculty of Life Sciences, Center for Metabolic Regulation of Healthy Aging Kumamoto University Kumamoto Japan.
ORCID-Profile: Naoto Kuyama, Seiji Takashio, Masahiro Yamamoto, Kyoko Hirakawa, Masanobu Ishii, Shinsuke Hanatani, Seitaro Oda, Yasushi Matsuzawa, Hiroki Usuku, Toshinori Hirai, Mitsuharu Ueda, Kenichi Tsujita
Zitieren
APA
Kuyama, N., Takashio, S., Oguni, T., Yamamoto, M., Hirakawa, K., Ishii, M., Hanatani, S., Oda, S., Matsuzawa, Y., Usuku, H., Yamamoto, E., Hirai, T., Ueda, M., & Tsujita, K. (2024). Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.034518
Vancouver
Kuyama N, Takashio S, Oguni T, Yamamoto M, Hirakawa K, Ishii M, et al. Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy. Journal of the American Heart Association. 2024. doi:10.1161/jaha.124.034518
BibTeX
@article{Kuyama2024,
author = {Kuyama, Naoto and Takashio, Seiji and Oguni, Tetsuya and Yamamoto, Masahiro and Hirakawa, Kyoko and Ishii, Masanobu and Hanatani, Shinsuke and Oda, Seitaro and Matsuzawa, Yasushi and Usuku, Hiroki and Yamamoto, Eiichiro and Hirai, Toshinori and Ueda, Mitsuharu and Tsujita, Kenichi},
title = {Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy},
journal = {Journal of the American Heart Association},
year = {2024},
doi = {10.1161/jaha.124.034518}
}
EUVIMED